NEW YORK (Reuters) - Merck and Co <MRK.N> issued a more cautious 2010 profit outlook on Friday and reported disappointing second-quarter sales of its vaccines and Singulair asthma drug, sending...
Read Full Story »
Merck & Co.'s chief executive, who oversaw the drug maker's acquisition of Schering-Plough Corp. last fall, received a compensation package valued at $11.9 million in 2009, according to an...
Read Full Story »
Merck & Co., a Dow component and the world's second-biggest drugmaker by revenue, reports fourth-quarter results before the stock market opens Tuesday. WHAT TO WATCH FOR: Key items will be profit...
Read Full Story »